Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALN 5288

Next Previous
Drug Profile

ALN 5288

Alternative Names: ALN-5288

Latest Information Update: 31 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Antidementias; Drug conjugates; Small interfering RNA
  • Mechanism of Action Protein expression modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 14 Oct 2025 Preclinical trials in Alzheimer's disease in USA (Intrathecal)
  • 09 Oct 2025 Alnylam Pharmaceuticals plans a phase I trial for Alzheimer's disease (AD) in Canada, Netherlands, Spain, United Kingdom (Intrathecal), in October 2025 (NCT07214727; CTIS2025-522582-30-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top